Bo Åhrén

41.3k total citations · 7 hit papers
720 papers, 33.1k citations indexed

About

Bo Åhrén is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Bo Åhrén has authored 720 papers receiving a total of 33.1k indexed citations (citations by other indexed papers that have themselves been cited), including 391 papers in Endocrinology, Diabetes and Metabolism, 387 papers in Surgery and 219 papers in Molecular Biology. Recurrent topics in Bo Åhrén's work include Pancreatic function and diabetes (322 papers), Diabetes Treatment and Management (267 papers) and Neuropeptides and Animal Physiology (179 papers). Bo Åhrén is often cited by papers focused on Pancreatic function and diabetes (322 papers), Diabetes Treatment and Management (267 papers) and Neuropeptides and Animal Physiology (179 papers). Bo Åhrén collaborates with scholars based in Sweden, United States and Denmark. Bo Åhrén's co-authors include Maria Sörhede Winzell, Jens J. Holst, Giovanni Pacini, F. Sundler, Anja Schweizer, James E. Foley, Gerald J. Taborsky, Suad Efendić, Carolyn F. Deacon and Ingmar Lundquist and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Bo Åhrén

714 papers receiving 32.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interleukin-6-deficient mice develop mature-onset obesity

2002 987 citations Bo Åhrén et al. profile →
The High-Fat Diet–Fed Mouse

2004 805 citations Maria Sörhede Winzell, Bo Åhrén profile →
Antidiabetogenic Effect of Glucagon-like Peptide-1 (7–36)amide in Normal Subjects and Patients with Diabetes Mellitus

1992 725 citations Bo Åhrén et al. profile →
Autonomic regulation of islet hormone secretion - Implications for health and disease

2000 700 citations Bo Åhrén Diabetologia profile →
Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes

2004 607 citations Bo Åhrén, Anja Schweizer et al. profile →
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease

2004 561 citations Bo Åhrén et al. profile →
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial

2017 368 citations Bo Åhrén et al. profile →

Peers

Countries citing papers authored by Bo Åhrén

Since Specialization

Citations

This map shows the geographic impact of Bo Åhrén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bo Åhrén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bo Åhrén more than expected).

Fields of papers citing papers by Bo Åhrén

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bo Åhrén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bo Åhrén. The network helps show where Bo Åhrén may publish in the future.

Co-authorship network of co-authors of Bo Åhrén

This figure shows the co-authorship network connecting the top 25 collaborators of Bo Åhrén. A scholar is included among the top collaborators of Bo Åhrén based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bo Åhrén. Bo Åhrén is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Short-term pre-meal whey protein microgel supplementation reduces postprandial glycemia and appetite in adults with overweight: An open-label randomised controlled trial 2025 ·PubMed ·Ian J. Neeland, Kostas Tsintzas, Bo Åhrén, Robert Ćhilton, (unknown), (unknown), (unknown), Eugenia Migliavacca, David Philippe, Olivier Aprikian, Odd Erik Johansen	0
2	A Randomized, Placebo-Controlled, Single-Center, Crossover Study to Evaluate the Effects of Pre-Meal Whey Protein Microgel on Post-Prandial Glucometabolic and Amino Acid Response in People with Type 2 Diabetes and Overweight or Obesity 2025 ·Metabolites ·Ian J. Neeland, Luiz Henrique de Gregório, (unknown), Bo Åhrén, Joel Neutel, Christian Darimont, John Corthésy, (unknown), (unknown), Maximilian von Eynatten, Odd Erik Johansen	3
3	Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy 2023 ·Diabetologia ·Matthias H. Tschöp, Rubén Nogueiras, Bo Åhrén	46
4	Contribution of GIP and GLP-1 to the Insulin Response to Oral Administration of Glucose in Female Mice 2023 ·Biomedicines ·Bo Åhrén	3
5	Hepatic and Extrahepatic Insulin Clearance in Mice with Double Deletion of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Receptors 2021 ·Biomedicines ·Micaela Morettini, (unknown), Laura Burattini, Giovanni Pacini, Christian Göbl, Bo Åhrén, Andrea Tura	1
6	Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI‐liraglutide study 5) 2018 ·Obesity Science & Practice ·(unknown), Karin Filipsson, (unknown), (unknown), Henrik Imberg, Stefan Sjöberg, Bo Åhrén, Sofia Dahlqvist, Thomas Gustafsson, Jaakko Tuomilehto, Irl B. Hirsch, Marcus Lind	12
7	Effects of DPP ‐4 inhibitor linagliptin and GLP ‐1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open‐label, 2‐arm parallel comparative, exploratory trial 2016 ·Diabetes Obesity and Metabolism ·Daisuke Yabe, Takashi Eto, Masanari Shiramoto, Shin Irie, Kenta Murotani, Yusuke Seino, Hitoshi Kuwata, Takeshi Kurose, Susumu Seino, Bo Åhrén, Yutaka Seino	24
8	CART is a novel glucose-dependent peptide with antidiabetic actions in humans 2015 ·Diabetologia ·Mia Abels, Matteo Riva, (unknown), Hedvig Bennet, Vini Nagaraj, Oleg Dyachok, Bo Isomaa, Jaakko Tuomilehto, Bo Åhrén, Anders Tengholm, Malin Fex, Erik Renström, Leif Groop, V. Lyssenko, Nils Wierup	1
9	CART is upregulated in islets of type 2 diabetic patients, stimulates insulin secretion, inhibits glucagon secretion and protects against beta cell death 2010 ·Lund University Publications (Lund University) ·Ramasri Sathanoori, Ulrikke Voss, Matteo Riva, Maria Sörhede Winzell, Bo Åhrén, Olle Korsgren, Nils Wierup	1
10	Diurnal variation in the incretin response to a meal challenge in humans 2008 ·Lund University Publications (Lund University) ·Ola Lindgren, Maria Sörhede Winzell, Carolyn F. Deacon, Bo Åhrén	1
11	Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin 2008 ·Vascular Health and Risk Management ·Bo Åhrén	61
12	Vildagliptin improves alpha cell glucose sensing in patients with type 2 diabetes 2008 ·Lund University Publications (Lund University) ·Bo Åhrén, Anja Schweizer, S. Dejager, Beth E. Dunning, Margaretha Persson, James E. Foley	6
13	Leptin Levels in Obese and Non-Obese African and Caucasian Subjects With Type 2 Diabetes 2004 ·International Journal of Endocrinology and Metabolism ·Zulfiqarali G. Abbas, Janet Lutale, Bo Åhrén	2
14	Body Adiposity, Insulin, and Leptin in Subgroups of Peruvian Amerindians 2004 ·High Altitude Medicine & Biology ·Folke Lindgärde, (unknown), (unknown), Bo Åhrén	51
15	Low CSF leptin in female suicide attempters with major depression 2003 ·Journal of Affective Disorders ·Sofie Westling, Bo Åhrén, Lil Träskman‐Bendz, Åsa Westrin	74
16	A Transplantable Human Carcinoid as Model for Somatostatin Receptor-Mediated and Amine Transporter-Mediated Radionuclide Uptake 2001 ·American Journal Of Pathology ·Lars Kölby, Peter Bernhardt, Håkan Ahlman, Bo Wängberg, Viktor Johanson, (unknown), Eva Forssell‐Aronsson, Sven Karlsson, Bo Åhrén, Göran Stenman, Ola Nilsson	91
17	Dual Action of the Neuropeptide Galanin on the Cytoplasmic Free Calcium Concentration in RIN m5F Cells 1993 ·Biochemical and Biophysical Research Communications ·(unknown), Bo Åhrén	17
18	Reduction of secretion from a small-bowel fistula by somatostatin. Case report. 1989 ·PubMed ·Bo Åhrén, Bruno Walther	2
19	Diabetes mellitus at a rural hospital in northwestern Tanzania. 1984 ·PubMed ·Bo Åhrén	8
20	Effects of vasoactive intestinal polypeptide (VIP), secretin and gastrin on insulin secretion in the mouse 1981 ·Diabetologia ·Bo Åhrén, Ingmar Lundquist	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact